The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
Abstract
Purpose: To assess long-term cause-specific mortality of young Hodgkin’s disease (HD) patients. Patients and Methods: The study population consisted of 1,261 patients treated for HD before age 41 between 1965 and 1987. Follow-up was complete until October 2000. For 95% of deaths, the cause was known. Long-term cause-specific mortality was compared with general population rates to assess relative risk (RR) and absolute excess risk (AER) of death. Results: After a median follow-up of 17.8 years, 534 patients had died (55% of HD). The RR of death from all causes other than HD was 6.8 times that of the general population, and still amounted to 5.1 after more than 30 years. RRs of death resulting from solid tumors (STs) and cardiovascular disease (CVD) were increased overall (RR = 6.6 and 6.3, respectively), but especially in patients treated before age 21 (RR = 14.8 and 13.6, respectively). When these patients grew older, this elevated mortality decreased. The overall AER of death from causes other than HD increased throughout follow-up. Patients receiving salvage chemotherapy had a significantly increased RR of death from STs, compared to patients receiving initial therapy only. Conclusion: The main cause of death among HD patients was lymphoma, but after 20 years, HD mortality was negligible. The RRs and AERs of death from second primary cancers (SCs) and CVDs continued to increase after 10 years. Even more than 30 years after diagnosis, HD patients experienced elevated risk of death from all causes other than HD. Increased risk of death from SCs and CVDs was found especially in patients treated before age 21, but these risks seemed to abate with age.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Factors Affecting Late Mortality From Heart Disease After Treatment of Hodgkin's Disease
Hancock, S. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510160067031 · Cited by 773
Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.038 · Cited by 565
Self-citationLung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease
Travis, L. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.182 · Cited by 562
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Self-citationSwerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., Horwich, A., Lister, T. A., & Linch, D. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.498 · Cited by 476
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Self-citationvan Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Self-citationNg, A. K., Bernardo, M. P., Weller, E., Backstrand, K. H., Silver, B., Marcus, K. C., Tarbell, N. J., Friedberg, J., Canellos, G. P., & Mauch, P. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.021 · Cited by 422
Leukemia After Therapy With Alkylating Agents for Childhood Cancer2
Tucker, M. A., Meadows, A. T., Boice, J. D., Stovall, M., Oberlin, O., Stone, B. J., Birch, J., Voûte, P. A., Hoover, R. N., Fraumeni, J. F., et al. (1987) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/78.3.459 · Cited by 352
Second Cancers Among Long-Term Survivors of Hodgkin’s Disease Diagnosed in Childhood and Adolescence
Metayer, C., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., Joensuu, T., van Leeuwen, F. E., van’t Veer, M. B., Curtis, R. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2435 · Cited by 340
Self-citationCoronary artery disease mortality in patients treated for hodgkin's disease
Boivin, J., Hutchison, G. B., Lubin, J. H., & Mauch, P. (1992) · Cancer · doi:10.1002/cncr.2820690528 · Cited by 278
Specht, L., Gray, R. G., Clarke, M. J., & Peto, R. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.830 · Cited by 239
Roles of Radiotherapy and Smoking in Lung Cancer Following Hodgkin's Disease
van Leeuwen, F. E., Klokman, W. J., Stovall, M., Hagenbeek, A., van den Belt-Dusebout, A. W., Noyon, R., Boice, J. D., Burgers, J. M. V., & Somers, R. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.20.1530 · Cited by 234
Self-citationvan Leeuwen, F. E., Chorus, A. M., van den Belt-Dusebout, A. W., Hagenbeek, A., Noyon, R., van Kerkhoff, E. H., Pinedo, H. M., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.5.1063 · Cited by 189
Self-citationLong-term complications of treatment and causes of mortality after Hodgkin's disease
Hancock, S. L., & Hoppe, R. T. (1996) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(96)80018-x · Cited by 179
Mauch, P. M., Kalish, L. A., Marcus, K. C., et al. (2006) · PubMed · Cited by 138
Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease.
Beaty, O., Hudson, M. M., Greenwald, C., Luo, X., Fang, L., Wilimas, J. A., Thompson, E. I., Kun, L. E., & Pratt, C. B. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.603 · Cited by 130
Breast cancer risk following irradiation for Hodgkin’s disease
Clemons, M. J., Loijens, L., & Goss, P. E. (2000) · Cancer Treatment Reviews · doi:10.1053/ctrv.2000.0174 · Cited by 114
Diller, L., Medeiros-Nancarrow, C., Shaffer, K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.031 · Cited by 110
Hoppe, R. T., FUKS, Z. Y., Strober, S., & Kaplan, H. S. (1977) · Cancer · Cited by 70
Hūirny, C., Bernhard, J., Coates, A. S., Castiglione, M., Peterson, H. F., Gelber, R. D., Rudenstam, C., Goldhirsch, A., & Senn, H.-J. (1994) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058697 · Cited by 25
Cited by
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Stewart, F. A., Akleyev, A. V., Hauer-Jensen, M., Hendry, J. H., Kleiman, N. J., MacVittie, T. J., Aleman, B. M., Edgar, A. B., Mabuchi, K., Muirhead, C. R., et al. (2012) · Annals of the ICRP · doi:10.1016/j.icrp.2012.02.001 · Cited by 1,604
Self-citationRadiation Dose–Volume Effects in the Heart
Gagliardi, G., Constine, L. S., Moiseenko, V., Correa, C., Pierce, L. J., Allen, A. M., & Marks, L. B. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.04.093 · Cited by 1,227
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Self-citationEngert, A., Haverkamp, H., Kobe, C., Markova, J., Renner, C., Ho, A., Zijlstra, J., Král, Z., Fuchs, M., Hallek, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61940-5 · Cited by 635
Metadata
- Authors
- Aleman, B. M. P., van den Belt-Dusebout, A. W., Klokman, W. J., van’t Veer, M. B., Bartelink, H., & van Leeuwen, F. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-09-15
- Volume
- 21
- Issue
- 18
- Pages
- 3431-3439
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2085143233
- Cited by
- 716
- References
- 23
- FWCI
- 15.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.